Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction

Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction

Abstract Aims Improving the health status (symptoms, function, and quality of life) of patients with heart failure with reduced ejection fraction (HFrEF) is a primary treatment goal. Angiotensin receptor neprilysin inhibitors (ARNI) improve short‐term health status in clinical practice, but the sust...

Full description

Bibliographic Details
Main Authors: Merrill Thomas, Yevgeniy Khariton, Gregg C. Fonarow, Suzanne V. Arnold, Larry Hill, Michael E. Nassif, Paul S. Chan, Javed Butler, Laine Thomas, Adam D. DeVore, Adrian F. Hernandez, Nancy M. Albert, J. Herbert Patterson, Fredonia B. Williams, John A. Spertus
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:ESC Heart Failure
Subjects:
Heart failure reduced ejection fraction
Quality of life
Health status
Angiotensin‐neprilysin inhibitor
Online Access:https://doi.org/10.1002/ehf2.13298

Internet

https://doi.org/10.1002/ehf2.13298

Similar Items